Physiomics Awarded New Contract by Numab

AI SummaryClose X

Physiomics plc has secured a new contract with Numab Therapeutics AG to develop a pharmacokinetic-pharmacodynamic (PK/PD) model for a key asset in Numab's Immunology and Inflammation pipeline. This collaboration aims to accelerate therapeutic development by informing the Target Candidate Profile and supporting early-stage, data-driven decision-making, with completion anticipated in the second quarter of 2026.

Disclaimer*

Companies

Physiomics (PYC)
UK 100

Latest directors dealings